Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas Raymond S.; Kahaly G.; Patel Amy; Sile S.; Thompson E. H.; Perdok R.; Fleming J.; Fowler B.; Marcocci C.; Marinò M.; Antonelli A.; Dailey R.; Harris G.; Eckstein A.; Schiffman J.; Tang R.; Nelson C.; Salvi M.; Wester S.; Sherman J.; Vescio T.; Holt R.; Smith Terry J.

doi:10.1056/nejmoa1910434

← Today's brief

L2 Study

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas Raymond S. et al. · The New England journal of medicine · Wednesday, January 1, 2020

Read original

Design Level 2n 41Funding Independent

Source

Douglas Raymond S. et al.. Teprotumumab for the Treatment of Active Thyroid Eye Disease. The New England journal of medicine. Wednesday, January 1, 2020.
doi:10.1056/nejmoa1910434

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.